Legend Biotech's SWOT analysis: carvykti's strong performance drives stock potential

Legend Biotech (LEGN) is experiencing strong growth driven by its multiple myeloma treatment, Carvykti, with sales nearly doubling in 2024 and projected to reach $1.9 billion in 2025 amid manufacturing expansion. The company, partnered with J&J to increase Carvykti production to 10,000 doses by the end of 2025, also has a diverse pipeline including LB1908 and LB2102, targeting other cancers. While competition from Anito-cel exists and safety concerns around neurotoxicities persist, analysts maintain a Strong Buy consensus with price targets ranging from $71 to $94, citing Carvykti's established efficacy and potential expansion into earlier treatment lines.

Analysis

Legend Biotech Corporation (LEGN) is demonstrating significant commercial momentum with its flagship multiple myeloma (MM) cell therapy, Carvykti, which nearly doubled sales year-over-year in 2024 and is projected to reach $1.9 billion in 2025, having treated approximately 4,500 patients. The therapy's strong efficacy, particularly an overall survival benefit in second-line and beyond (2L+) settings and a 45% reduction in all-cause mortality at 30 months per CARTITUDE-4 data, underpins its growing adoption, further supported by nearly half of treatments occurring in outpatient settings. A critical factor for continued growth is the manufacturing expansion in partnership with Johnson & Johnson, aiming for 10,000 autologous doses by the end of 2025 and potentially over $10 billion in product value by 2027. Financially, LEGN maintains a robust cash position exceeding debt (current ratio 5.2x) and anticipates profitability by Q2 2026, despite a current gross profit margin of 8.6%. The company's pipeline, featuring LB1908 for gastric/esophageal cancer and LB2102 for small cell lung cancer, offers diversification and long-term growth avenues, with positive Phase I data presented. However, challenges persist, including potential manufacturing scalability issues, safety concerns related to neurotoxicities (such as a ~2% Parkinsonism rate observed in real-world studies), and intensified competition, notably from Anito-cel, which has shown comparable efficacy with a different safety profile. Analyst sentiment remains strongly positive, with a 'Strong Buy' consensus and price targets ranging from $71 to $94, reflecting confidence in Carvykti's market leadership and expansion potential into earlier treatment lines.

Key Decisions for Investors

• Investors should monitor Legend Biotech's execution on Carvykti manufacturing scale-up targets, as achieving the planned 10,000 doses by late 2025 is crucial for meeting demand and revenue projections.
• Closely track comparative safety and efficacy data updates for Carvykti versus competitor Anito-cel, particularly regarding neurotoxicity profiles, as this will significantly influence market share dynamics and physician adoption in multiple myeloma treatment.
• Consider the company's progress towards its Q2 2026 profitability target and monitor clinical trial advancements for pipeline assets LB1908 and LB2102, as these are key catalysts for long-term valuation and diversification beyond Carvykti.
• Evaluate the pace of Carvykti's adoption in earlier lines of multiple myeloma treatment, as success in this area represents a substantial expansion of its addressable market and revenue potential.